Skip to main content

Slide Stainer Market worth $5.9 billion in 2027 – Exclusive Report by MarketsandMarkets™

Chicago, Oct. 03, 2022 (GLOBE NEWSWIRE) — Slide Stainer Market is projected to grow from USD 4.3 billion in 2022 to USD 5.9 billion by 2027, at a CAGR of 6.8% from 2022 to 2027, according to a new report by MarketsandMarkets™. Growth in this market can be attributed to the expanding population of geriatric patients, increasing research investments into cancer and cancer drugs, the high volume of cancer biopsies, and the high prevalence of cancer, chronic diseases and infections.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134046412

Browse in-depth TOC on “Slide Stainer Market
194 – Tables
45 – Figures
226 – Pages

In 2021, reagents & kits accounted for the largest share of the slide stainer market, by product.

By product, the slide stainer market is segmented into reagents, equipment, and consumables & accessories. The reagents & kits segment accounted for the highest share, which is attributed to its massive demand for slide staining amid the pandemic for lung pathology studies and cancer biopsies. Reagents are highly consumed for research and diagnosis of various complications such as cancer, infections and other chronic medical conditions.

The disease diagnosis application accounted for the largest market share in 2021.

Based on the application, the slide stainer market is segmented into disease diagnosis and medical research. The other application segment held the largest share. The disease diagnosis dominated the slide stainer applications with cancer diagnoses (such as breast cancer, gastric cancer, and lymphoma) and infections.

By technology, hospitals accounted for the largest market share in 2021.

Based on technology, the market is segmented into cytology, immunohistochemistry, hematoxylin & eosin (H&E), in situ hybridization, microbiology, hematology, and special staining. In 2021, hematoxylin & eosin ruled the market with their massive application in the area of slide staining. H&E is the most widely used technique for staining biological samples or tissues.

Among end users, hospitals accounted for the largest market share in 2021.

Based on end user, the market is segmented into hospitals and diagnostics centers, academic and research institutes, pharmaceutical and biotechnology companies, and other end users. In 2021, the hospitals and diagnostics centers segment dominated the end users of the slide stainer market with the massive volume of cancer and infectious diseases diagnoses.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=134046412

North America was the largest regional market for slide stainer market in 2021.

The slide stainers market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of the market in 2021, followed by Europe. North America dominates the market with its high incidence of a strong presence of slide stainer companies, the massive burden of chronic and infectious diseases, and advanced healthcare infrastructure in the region.

Some of the major players operating in the slide stainer market are F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), PHC Holdings Corporation (Japan), Thermo Fisher Scientific, Inc. (US), Merck KGAA (Germany), Agilent Technologies, Inc. (US), Abcam Plc. (UK), Becton, Dickinson and Company (US), Siemens Healthineers AG (Germany), Biocare Medical, LLC (US), Hardy Diagnostics (US), General Data Company (US), ELITechGroup (France), Biogenex (US), Histo-Line Laboratories (Italy), SLEE medical GmbH (Germany), Amos scientific Pty Ltd. (Australia), MEDITE Medical GMBH (Germany), Cellpath Ltd (UK), Diapath S.P.A. (Italy), Bio SB, Inc. (US), Rockland Immunochemicals, Inc. (US), Cell Signaling Technology, Inc. (US), Diagnostic BioSystems, Inc. (US), and Dakewe Biotech Co., Ltd. (China).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=134046412

Browse Adjacent Market: Analytical and Scientific Instrumentation Market Research Reports & Consulting

Related Reports:

Immunohistochemistry (IHC) Market by Product (Antibodies, Reagents, Equipment, Kits), Application (Diagnostics (Cancer, Infectious, Autoimmune Diseases), Research, Forensic), End user (Hospitals, Diangostic labs, Academia) – Global Forecast to 2026

CONTACT: About MarketsandMarkets™ 

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.